Table 4.
All-cause mortality | Breast cancer-specific mortality | |||||||
---|---|---|---|---|---|---|---|---|
Fully Adjusted HR (95% CI) | 5-year survival Probability (95% CI) | Fully Adjusted HR (95% CI) | 5-year survival Probability (95% CI) | |||||
CALIFORNIA | ||||||||
Nativity | ||||||||
US Born (ref) | 1.00 | 0.926 | (0.919–0.932) | 1.00 | 0.980 | (0.976–0.983) | ||
Foreign Born | 1.12 | (1.07–1.17) | 0.918 | (0.911–0.924) | 1.17 | (1.10–1.25) | 0.976 | (0.973–0.980) |
Joint nSES/ enclave measure | ||||||||
High SES, Enclave | 0.89 | (0.84–0.95) | 0.934 | (0.927–0.940) | 0.95 | (0.87–1.03) | 0.981 | (0.977–0.984) |
High SES, Non-Enclave | 0.85 | (0.81–0.89) | 0.936 | (0.931–0.941) | 0.89 | (0.83–0.95) | 0.982 | (0.979–0.984) |
Low SES, Enclave (ref) | 1.00 | 0.926 | (0.919–0.932) | 1.00 | 0.980 | (0.976–0.983) | ||
Low SES, Non-Enclave | 1.15 | (1.06–1.26) | 0.914 | (0.904–0.922) | 1.13 | (1.00–1.28) | 0.977 | (0.972–0.981) |
TEXAS | ||||||||
Nativity | ||||||||
US Born (ref) | 1.00 | 0.909 | (0.900–0.917) | 1.00 | 0.977 | (0.972–0.981) | ||
Foreign Born | 1.17 | (1.09–1.25) | 0.895 | (0.884–0.905) | 1.26 | (1.16–1.37) | 0.971 | (0.965–0.977) |
Joint nSES/ enclave measure | ||||||||
High SES, Enclave | 0.91 | (0.85–0.97) | 0.917 | (0.909–0.925) | 0.94 | (0.86–1.02) | 0.979 | (0.974–0.982) |
High SES, Non-Enclave | 0.90 | (0.85–0.96) | 0.917 | (0.909–0.925) | 0.94 | (0.87–1.02) | 0.978 | (0.974–0.982) |
Low SES, Enclave (ref) | 1.00 | 0.909 | (0.900–0.917) | 1.00 | 0.977 | (0.972–0.981) | ||
Low SES, Non-Enclave | 1.09 | (0.97–1.23) | 0.900 | (0.885–0.913) | 1.06 | (0.92–1.22) | 0.975 | (0.969–0.980) |
Fully adjusted models include age at diagnosis, tumor grade, tumor size, year of diagnosis, histology, underlying stratification by stage and clustering by census tract.